VANCOUVER, British Columbia--(BUSINESS WIRE)--
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will participate in three upcoming investor conferences.
- Wells Fargo Securities’ 14th Annual Healthcare Conference is scheduled for September 4-5, 2019 in Boston, MA. Zymeworks is presenting on Wednesday, September 4, 2019 at 8:30 a.m. ET.
- Citi’s 14th Annual Biotech Conference is scheduled for September 4-5, 2019 in Boston, MA.
- Ladenburg Thalmann’s Healthcare Conference is scheduled for September 24, 2019 in New York, NY. Zymeworks is presenting on Tuesday, September 24, 2019 at 10:30 a.m. ET.
The Company will provide a corporate update and present upcoming catalysts. Interested parties can access a live webcast of the presentations via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host recorded replays available afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.